Journal Article

Successful Induction of Protective Antibody Responses against <i>Haemophilus influenzae</i> Type b and Diphtheria after Transcutaneous Immunization with the Glycoconjugate Polyribosyl Ribitol Phosphate—Cross-Reacting Material<sub>197</sub> Vaccine

Fatme Mawas, Marisa Peyre, Anne-Sophie Beignon, Laura Frost, Giuseppe Del Giudice, Rino Rappuoli, Sylviane Muller, Dorothea Sesardic and Charalambos D. Partidos

in The Journal of Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 190, issue 6, pages 1177-1182
Published in print September 2004 | ISSN: 0022-1899
Published online September 2004 | e-ISSN: 1537-6613 | DOI: http://dx.doi.org/10.1086/423327
Successful Induction of Protective Antibody Responses against Haemophilus influenzae Type b and Diphtheria after Transcutaneous Immunization with the Glycoconjugate Polyribosyl Ribitol Phosphate—Cross-Reacting Material197 Vaccine

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

We examined the antibody responses elicited in rats after transcutaneous immunization (TCI) with the Haemophilus influenzae type b (Hib)-cross-reacting material (CRM197) glycoconjugate vaccine coadministered with cholera toxin or mutants of heat-labile enterotoxin of Escherichia coli (LTK63 and LTR72) as adjuvants. The glycoconjugate vaccine was immunogenic, eliciting high antibody responses to the capsular polysaccharide of Hib and to diphtheria toxin. Passively transferred immune serum protected infant rats against challenge with the Hib Eagan strain and exhibited strong neutralizing activity against diphtheria toxin both in vitro and in vivo. The finding that TCI of rats can elicit antibody responses surpassing the minimum levels required for protective immunity against Hib and diphtheria suggests that this immunization strategy holds a lot of promise for future pediatric use. However, further studies are required to confirm the potential of TCI with glycoconjugate vaccines in humans.

Journal Article.  3678 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.